

1 **Human Papillomavirus Vaccination Awareness and Uptake among Healthcare Students in**
2 **Japan**

3

4 Madoka Shimbe^a, Yuki Otsuka^a, Hideharu Hagiya^{b*}, Yoichi Yamada^c, Fumio Otsuka^{a,b}

5

6 ^aDepartment of General Medicine, Okayama University Graduate School of Medicine, Dentistry
7 and Pharmaceutical Sciences, Okayama, 700-8558, Japan

8 ^bDepartment of Infectious Diseases, Okayama University Hospital, Okayama, 700-8558, Japan

9 ^cSchool of Pharmacy, Shujitsu University, Okayama 703-8516, Japan

10

11 ***Corresponding author:**

12 Hideharu Hagiya, MD, PhD

13 Department of Infectious Diseases, Okayama University Hospital

14 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan

15 Telephone: +81-86-235-7342 Fax: +81-86-235-7345

16 E-mail: hagiya@okayama-u.ac.jp

17

18 **ICMJE Statement**

19 HH conceived the study; MS, YO, YY, and HH collected the data; MS and YO drafted the
20 manuscript; HH revised the manuscript; FO supervised the study. All authors interpreted the
21 results, contributed to the writing of the manuscript, and gave final approval to the submitted
22 manuscript.

23

24 **Abstract**

25 **Background:** The vaccination rate for HPV (Human Papillomavirus) has remained significantly
26 low in Japan because of the administrative suspension of active recommendation. This study
27 investigates the awareness and uptake of the HPV vaccine among healthcare students in Japan
28 following the reinstatement of active recommendation for young women in April 2022.

29 **Methods:** A web-based survey was administered to 2,567 healthcare students from Okayama and
30 Shujitsu Universities in Japan in July 2023. The survey assessed participants' backgrounds,
31 immunization status, awareness of vaccine recommendations, and knowledge of cervical cancer
32 across various demographics, including sex, academic year, and department (Medicine, Health
33 Science, Pharmaceutical, and Dentistry).

34 **Results:** The response rate was 36.3% (933 students; 181 male, 739 female, and 13 unspecified
35 gender). The overall immunization rate among female students was 55.6%, with higher rates
36 observed in medical (73.8%) and dental (63.0%) students. Awareness of the government's change
37 in vaccine recommendation was notably high among female and senior male students. Over half
38 of the female students (54.7%) reported receiving vaccinations based on their parents' advice.
39 Among those unvaccinated but interested in future immunization, concerns about adverse
40 reactions (47.4%) and challenges in scheduling vaccinations (29.1%) were predominant.

41 **Conclusion:** Healthcare students exhibited a higher HPV vaccination rate than the general
42 population. Ongoing education to improve vaccine literacy is crucial for augmenting HPV
43 vaccination rates in Japan.

44

45 **Keywords:** Cervical cancer, Human Papillomavirus, Immunization, Vaccine literacy

46

47 **Introduction**

48 The Human Papillomavirus (HPV) vaccine is recognized as the sole preventative measure against
49 the development of cervical cancer [1-3]. In Western countries—where the HPV vaccine has been
50 extensively incorporated into public health policies—a significant decrease in the incidence of
51 cervical cancer has been documented [4-6]. Conversely, in Japan, despite the implementation of
52 routine vaccination for individuals **equivalent to 6th grade of elementary school to 1st grade of**
53 **high school** in April 2013 under the Immunization Act, widespread media coverage of adverse
54 events—including syncope, chronic fatigue, and post-vaccination pain—contributed to increased
55 vaccine hesitancy [6-10]. This led governmental authorities to suspend active recommendations
56 in June of the same year [11]. As a result, the HPV vaccination rate in Japan has stagnated at less
57 than 1%, leading to a rise in the incidence of cervical cancer [4,12].

58 Scientific research has substantiated the lack of a causal link between HPV vaccination
59 and adverse events, leading to the reinstatement of active immunization endorsements in Japan in
60 April 2022 [13]. Subsequently, from April 2023, three types of HPV vaccines (bivalent,
61 quadrivalent, and nonavalent) have been determined as complimentary routine vaccines by the
62 Japanese government. Despite national policies highlighting the efficacy and safety of HPV
63 vaccines [14,15], entrenched perceptions of vaccine risks persist within the Japanese populace,
64 resulting in a consistently low immunization rate of approximately one-fourth among the younger
65 generations eligible for routine vaccination as of 2023 [16]. Furthermore, while catch-up
66 vaccinations are emphatically advocated for young women born between 1997 and 2006—who
67 were deprived of immunization opportunities during the period of recommendation suspension—
68 their immunization rates remain exceedingly low [16].

69 Enhancing the HPV vaccination rate represents a significant healthcare imperative in
70 Japan to curtail the escalating incidence of cervical cancer. Nonetheless, the factors shaping
71 individuals' adverse perceptions toward the HPV vaccine remain unclear. Equally uncertain is
72 how healthcare professionals—tasked with educating and informing the populace about the

73 vaccine's merits—acquire knowledge and awareness of the HPV vaccine during their
74 undergraduate curriculum. To guide future medical education and public outreach initiatives, this
75 study explores the HPV vaccination uptake, knowledge, and perceptions among healthcare
76 students, who are within the target age bracket for vaccination and training to become the next
77 generation of healthcare providers.

78

79 **Materials and Methods**

80 ***Study design***

81 This cross-sectional, descriptive study was conducted at two academic institutions in Okayama
82 Prefecture, Japan. We included all healthcare students enrolled in the regular courses of the
83 healthcare-associated faculties at Okayama University (a national institution) and Shujitsu
84 University (a private institution), enrolled in the Departments of Medicine, Health Sciences,
85 Pharmacy, and Dentistry, totaling 2,567 undergraduate students (comprising 1,060 male and 1,507
86 female), as of July 2023. We utilized Google Forms to distribute an electronic survey via email
87 and group chat applications to solicit participant responses. We conducted the survey
88 anonymously from July 7–31, 2023, and offered lottery gift cards valued at 2,000 Japanese Yen
89 to 20 randomly selected participants as an incentive.

90 ***Data Collection and Outcomes***

91 The questionnaire gathered background information on respondents—including their department,
92 academic year, age, and gender. The primary focus was to elicit participants' histories and
93 intentions regarding HPV vaccination, as well as reasons for their choices, through free-text
94 responses. The history of vaccinations was obtained based on self-reported responses. Secondary
95 assessments addressed awareness of the suspension or resumption of HPV vaccination
96 recommendations, participation in cervical cancer screenings, and self-evaluated knowledge
97 about cervical cancer, rated on a three-point scale (well-informed; familiar with the name only;

98 unaware). Free-text responses were analyzed and categorized by the researchers. An English-
99 translated questionnaire form is given as Supplementary material.

100 ***Statistical analysis***

101 Continuous variables were described as medians and interquartile ranges (IQRs). Categorical
102 variables were reported as numbers and percentages and were assessed using the Chi-square or
103 Fisher's exact test, as appropriate. The data were analyzed using EZR software, a graphic user
104 interface for the R 4.3.1 software (The R Foundation for Statistical Computing, Vienna, Austria)
105 [17]. All reported p values <0.05 were considered statistically significant.

106 ***Ethics approval***

107 The researchers obtained informed consent from the participants through the web survey and
108 included only those who provided consent in this study. Ethical approval was obtained from the
109 Ethics Committee of Okayama University Hospital (No. 2212-038), ensuring that the research
110 was conducted in alignment with the principles outlined in the Declaration of Helsinki.

111

112 **Results**

113 A total of 962 responses were received for the web survey. After excluding 14 responses from
114 individuals who did not provide consent to participate in the study, and 15 responses from students
115 not enrolled in regular courses, 933 responses were included in the study, resulting in a final
116 response rate of 36.3% (**Fig. 1**). The background information and response rates of the participants
117 is presented in **Table 1**. Of the 933 responses, 181 (19.4%) were from male students (with a
118 response rate of 17.1%), 739 (79.2%) were from female students (with a response rate of 49.0%),
119 and 13 (1.4%) were from participants of unspecified gender. The median age of respondents was
120 20 years [IQR: 19–21], with a mean age of 21.5 years in the Department of Medicine, 19.7 years
121 in the Department of Health Science, 22.0 years in the Department of Dentistry, and 20.7 years in
122 the Department of Pharmacy.

123 The HPV vaccination status of the students is provided in **Fig. 2**. In total, 411 female
124 (55.6%) and three male students (1.7%) had already received the HPV vaccination. Among the
125 respondents, 251 female (34.0%) and 46 male students (25.4%) intended to receive the vaccine.
126 A lack of interest in vaccination was indicated by 73 female (9.9%) and 129 male students (71.3%).
127 One female student (0.1%) and 12 male students (6.6%) answered they had never heard about the
128 HPV vaccine. The HPV vaccination rates varied among female students across different grades,
129 with the rate for 6th year female students (90.6%) being significantly higher than that of female
130 students in other grades; 51.9%, 47.6%, 48.5%, 60.0%, and 58.0% in the 1st, 2nd, 3rd, 4th, and 5th
131 years, respectively. The HPV vaccination proportion was significantly higher among Medical
132 students (73.8%) than among Health Science (49.1%) and Pharmaceutical students (53.1%).

133 Awareness among students regarding the history of policy change related to HPV
134 vaccine recommendations in Japan is depicted in **Fig. 3**. Stratified by gender, awareness among
135 females (660, 89.3%) was significantly higher than among males (100, 55.2%). Forty-seven male
136 students (26.0%) were unaware of both the suspension and reinstatement phases of the
137 vaccination policy, and twelve male students (6.6%) were entirely unaware of the existence of the
138 HPV vaccine. While no significant differences were observed across various academic levels
139 among female students, a notable ascending trend in awareness was identified among male
140 students with the advancement of their academic grades. Specifically, up to 85.3% of the male
141 students in their 6th year were informed about the historical changes in the vaccination policy in
142 Japan.

143 Subsequently, the results of healthcare students' self-assessment of their knowledge
144 regarding cervical cancer were presented in **Fig. 4**. Of the respondents, 116 (64.1%) male and 551
145 (74.6%) female students reported being well-informed about cervical cancer. Furthermore, 61
146 (33.7%) male and 187 (25.3%) female students indicated they had heard of the disease. The
147 proportion of students answering comprehensive knowledge about cervical cancer increased
148 significantly with academic progression, with percentages ascending from the 1st to 6th years at

149 57.4%, 54.6%, 76.8%, 81.8%, 91.4%, and 94.9%, respectively. Compared to Health Science
150 (73.0%) and Pharmaceutical students (64.7%), Medical students reported a higher level of
151 awareness of cervical cancer (81.9%).

152 **Fig. 5** shows the primary reasons for the HPV vaccination. Among the vaccinated
153 students, 165 (40.2%) reported that their decision to receive the vaccination was self-initiated,
154 while 225 students (54.7%) attributed their vaccination to parental influence. The remaining 21
155 students (5.1%) cited other reasons for vaccination, encompassing peer recommendations and
156 initiatives by local authorities.

157 The major reasons provided by unvaccinated students are summarized in **Table 2**. Of
158 the 251 students not vaccinated but considering future HPV vaccinations, 119 (47.4%) expressed
159 concern about potential adverse reactions. Forty-two students (16.7%) were not aware that the
160 HPV vaccine was available, and 90 students (35.9%) provided other explanations for their
161 unvaccinated status. These other reasons were classified based on their open-ended responses into
162 i) difficulties in arranging vaccination schedules (73 students, 29.1%), ii) a general disinclination
163 towards vaccinations or injections (7 students, 2.8%), and iii) dissenting opinions from family
164 members (5 students, 2.0%). Furthermore, of the 73 students who were unvaccinated and not
165 interested in vaccinations, 61 students (83.6%) indicated apprehension about adverse reactions as
166 the primary deterrent to considering having the vaccine in the future.

167

168 **Discussion**

169 In the present study, we investigated the cognizance and uptake of HPV vaccination among
170 healthcare students in Japan. Previous research has explored immunization rates and attitudes
171 towards HPV vaccination in Japan, utilizing surveys of particular cohorts or inquiries conducted
172 by municipalities [18-20]. Our effort is thus unique in focusing on healthcare students who are
173 assumed to have higher health literacy. Notably, the vaccination rate among female healthcare
174 students was 55.6%, with the rate reaching nearly 90% among 6th year students. The vaccination

175 rate among the Medical students was higher, at almost 70%, compared to their counterparts in
176 other affiliations. These results are consistent with previous research [5,20-22], indicating a high
177 vaccine literacy within these demographics.

178 Disparity in the awareness of the suspension and resumption of HPV vaccine
179 recommendation was observed between female and male students. Among the female population,
180 awareness of the policy changes related to the HPV vaccine was pervasive, even among students
181 in the earlier academic years. However, the awareness of male students increased with their
182 academic progression; from approximately 30% among 1st to 3rd year students to over 80% among
183 final-year students. These results suggest that female healthcare students were well informed
184 about the HPV vaccine before university matriculation. In contrast, HPV vaccine literacy among
185 male students in younger grades was equivalent to that of the general population, and they
186 acquired a deeper understanding of the HPV vaccine as they progressed in their medical education.
187 This suggests that medical education enhances awareness of the HPV vaccine, in addition to
188 generic awareness campaigns conducted by local governments [5,23].

189 In-depth discussion about the HPV vaccination is indispensable to encourage take-up.
190 Unlike routine vaccinations for children stipulated under Japan's Immunization Law, the HPV
191 vaccine primarily targets individuals aged 12–16 years, necessitating the involvement of both
192 parents and adolescents in the decision-making process. Thus, it is essential to approach both
193 parents and their teenagers to augment vaccination rates [5]. Parent literacy about the HPV
194 vaccine is also important for healthcare students to decide to undergo immunization. Over half of
195 the students opted for vaccination following their parent's recommendations, suggesting that the
196 family environment and parental vaccine literacy impacts students' vaccination behaviors [23].
197 Additionally, logistical challenges such as conflicts with school entrance exams, private events,
198 and relocations can obstruct vaccination efforts. Although mass vaccination in school settings is
199 prohibited in Japan, enhancements in this situation are anticipated to boost vaccination rates.

200 The absence of public subsidies and recommendations for male vaccination in Japan

201 may correlate with their lower interest. The present study indicates that the proportion of male
202 healthcare students with knowledge of the HPV vaccine increases with academic progression.
203 When vaccination rates among women are low, the cost-effectiveness of vaccinating men is
204 deemed to be substantial [24]. Medical professionals are also expected to disseminate accurate
205 information and elevate awareness, underscoring the necessity to initiate vaccination campaigns
206 for all students, including males, to potentially increase men's interest in the HPV vaccine. Some
207 local authorities in Japan have already commenced providing public funding for HPV
208 vaccinations for men.

209 The present study has some limitations. First, we only collected the data from two
210 Japanese universities, with a final eligible rate of 36.3%. Thus, the generalizability of the results
211 should be carefully evaluated. Second, the data was based on voluntary responses; thus, reporting
212 bias is inevitable. Additionally, there were disparities in response rates across faculties and
213 academic grades. Third, high immunization rates among higher-grade students may be attributed
214 more to their **year of birth** rather than their high literacy levels as healthcare students. Finally,
215 concerns about adverse reactions were identified as a significant reason for avoiding vaccination.
216 However, the details of this response could not be elucidated in this questionnaire-based study.

217 In conclusion, this study demonstrates that HPV vaccination rates among healthcare
218 students exceed those in the general population. Nearly 50% of female healthcare students had
219 already been vaccinated, and the remaining 40% of them were willing to be vaccinated. Although
220 male healthcare students exhibit less interest in HPV vaccination, acquiring knowledge about
221 cervical cancer through medical education may positively influence their vaccination behaviors.
222 To enhance HPV vaccination rates in Japan, it is deemed essential to ensure vaccination
223 opportunities and to implement educational activities targeting a broad audience—including
224 vaccine-target individuals and their parents.

225

226 **Acknowledgments**

227 The authors are grateful to the students answering the questionnaire, as well as the medical and
228 clerical staff of the universities. Especially, we would like to thank Dr. Kanako Ochi (Center for
229 Education in Medicine and Health Science, Okayama University) for her assistance. We would
230 like to thank Editage (www.editage.jp) for the English language editing.

231 **Funding**

232 We applied the management expense grant of the Department of General Medicine for the
233 lottery gift cards distributed to the respondents.

234 **Conflicts of interest**

235 The authors declare no competing interests.

236 **Availability of data and material**

237 Detailed data are available upon reasonable request to the corresponding author.

238 **Ethics approval**

239 Ethical approval was obtained from the Institutional Review Board of Okayama University
240 Hospital (No. 2212-038).

241 **Consent for publication**

242 Informed consent was obtained from the study participants through the questionnaire.

243

244

245 **References**

246 [1] Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk
247 of invasive cervical cancer. *N Engl J Med* 2020;383:1340–8.
248 <https://doi.org/10.1056/NEJMoa1917338>

249 [2] Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human
250 papillomaviruses to prevent cervical cancer and its precursors. *Cochrane Database Syst Rev*
251 2018;5:CD009069. <https://doi.org/10.1002/14651858>

252 [3] Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. Broad Spectrum
253 HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia
254 in women. *N Engl J Med* 2015;372:711–23. <https://doi.org/10.1056/NEJMoa1405044>

255 [4] Tanaka S, Palmer M, Katanoda K. Trends in cervical cancer incidence and mortality of
256 young and middle adults in Japan. *Cancer Sci.* 2022;113:1801–7.

257 [5] Terada M, Shimazu T, Saito J, Odawara M, Otsuki A, Yaguchi-Saito A, et al. Age, gender
258 and socioeconomic disparities in human papillomavirus (HPV) awareness and knowledge
259 among Japanese adults after a 7-year suspension of proactive recommendation for the HPV
260 vaccine: A nationally representative cross-sectional survey. *Vaccine.* 2023;41:7147–58.
261 <https://doi.org/10.1016/j.vaccine.2023.10.024>

262 [6] Sawada M, Ueda Y, Yagi A, et al. HPV vaccination in Japan: results of a 3-year follow-up
263 survey of Obstetricians and gynecologists regarding their opinions toward the vaccine. *Int J*
264 *Clin Oncol* 2018;23:121–5. <https://doi.org/10.1007/s10147-017-1188-9>

265 [7] Ueda Y, Enomoto T, Sekine M, Morimoto A, Nakae R, Kakubari R, et al. Japan's failure to
266 vaccinate girls against human Papillomavirus. *Am J Obstet Gynecol* 2015;212:405–6.
267 <https://doi.org/10.1016/j.ajog.2014.11.037>

268 [8] Yagi A, Ueda Y, Egawa-Takata T, Tanaka Y, Nakae R, Morimoto A, et al. Realistic fear of
269 Cervical cancer risk in Japan depending on birth year. *Hum Vaccin Immunother*
270 2017;13:1700–4. <https://doi.org/10.1080/21645515.2017.1292190>

271 [9] Inokuma Y, Kneller R. Imprecision in adverse event reports following immunization against
272 HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of vaccine
273 hesitancy and government policy. *Eur J Clin Pharmacol* 2023;79:269–78.
274 <https://doi.org/10.1007/s00228-022-03412-0> Google Scholar

275 [10] Sakanishi Y, Takeuchi J, Suganaga R, Nakayama K, Nishioka Y, Chiba H, et.al. Association
276 between administration or recommendation of the human papillomavirus vaccine and
277 primary care physicians' knowledge about vaccination during proactive recommendation
278 suspension: a nationwide cross-sectional study in Japan. *BMJ Open* 2023;13:e074305.
279 <https://doi.org/10.1136/bmjopen-2023-074305>

280 [11] Ministry of Health, Labour and Welfare of Japan. Correspondence about the routine
281 vaccination of human papilloma virus infection (recommendation). 2013 Available:
282 https://www.mhlw.go.jp/bunya/kenkou/kekakukansenshou28/pdf/kankoku_h25_6_01.pdf [Accessed 8 Mar 2023].

284 [12] Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy
285 on cervical cancer in Japan: a modelling study. *Lancet Public Health*. 2020;5:e223–34.
286 [https://doi.org/10.1016/S2468-2667\(20\)30010-4](https://doi.org/10.1016/S2468-2667(20)30010-4)

287 [13] World Health Organization. Global Advisory Committee on Vaccine Safety. Safety of HPV
288 vaccines. July 2017. Available: <https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/human-papillomavirus-vaccines/safety> (Accessed on January 14, 2024).

291 [14] Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and efficacy data
292 on vaccines and immunization to human Papillomavirus. *J Clin Med* 2015;4:614–33.
293 <https://doi.org/10.3390/jcm4040614>

294 [15] Centers for Disease Control and Prevention. HPV Vaccine Safety and Effectiveness Data,
295 Available: <https://www.cdc.gov/hpv/hcp/vaccine-safety-data.html> [Accessed 13 January
296 2024]

297 [16] Ministry of Health, Labour and Welfare of Japan. Survey on understanding in HPV
298 vaccine,2023 . Available: <https://www.mhlw.go.jp/content/10906000/001128683.pdf>
299 [Accessed 1January, 2024].

300 [17] Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical
301 statistics. *Bone Marrow Transplant* 2013;48:452–8.

302 [18] Suzuki T, Ota Y, Sakata N, Fujita N, Kamatsuka M, Nagashima K, et al. HPV vaccine
303 intention among university students during suspension of active recommendation in Japan.
304 *Hum Vaccin Immunother* 2022;18:2116900.
305 <https://doi.org/10.1080/21645515.2022.2116900>

306 [19] Irino S, Ose H, Takata N, Kamoshida S, Ohsaki H. Barriers to undergoing cervical cancer
307 screening among health sciences university students in Japan: A cross-sectional study. *Nurs
308 Health Sci* 2023;25:466–73. <https://doi.org/10.1111/nhs.13043>

309 [20] Horio F, Ikeda T, Zaitsu M, Takebe D, Tabata A, Matsukura M, et al. Knowledge and
310 Awareness of Human Papillomavirus Vaccination and Cervical Cancer among Men and
311 Women in Japan: A Questionnaire Survey. *Asian Pac J Cancer Prev* 2023;24:1063-71.
312 <https://doi.org/10.31557/APJCP.2023.24.3.1063>

313 [21] Alshehri MA, Fahim WA, Alsaigh RR. The association between parents' knowledge about
314 human papillomavirus and their intention to vaccinate their daughters: A cross-sectional
315 study. *Cureus* 2023;15:e48600. <https://doi.org/10.7759/cureus.48600>

316 [22] Suzuki Y, Sukegawa A, Nishikawa A, Kubota K, Motoki Y, Asai-Sato M, et al. Current
317 knowledge of and attitudes toward human papillomavirus-related disease prevention among
318 Japanese: A large-scale questionnaire study. *J Obstet Gynaecol Res* 2019;45:994–1005.
319 <https://doi.org/10.1111/jog.13929>

320 [23] Anandarajah A, Shato T, Humble S, Barnette AR, Brandt HM, Klesges LM, et al. The
321 association of caregiver attitudes, information sources, and trust with HPV vaccine initiation
322 among adolescents. *Hum Vaccin Immunother* 2024;20:2300879.
323 <https://doi.org/10.1080/21645515.2023.2300879>

324 [24] Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J. Direct benefit of
325 vaccinating boys along with girls against oncogenic human papillomavirus: bayesian
326 evidence synthesis. *BMJ* 2015;350:h2016. <https://doi.org/10.1136/bmj.h2016>

327

328

329 **Figure legend**

330 **Figure 1. Study flow**

331 A total of 2,567 healthcare students from two Japanese universities were invited to participate in
332 a web-based survey. After excluding 29 responses, 933 responses were included in the analysis.

333

334 **Figure 2. HPV vaccination status of healthcare students, by (A) sex, (B) academic year
335 (female), and (C) affiliated department (female)**

336 (A) The completion rate of HPV vaccination was significantly higher in female students.
337 (B) The completion rate of HPV vaccination in the final year (90.6%) was significantly higher
338 than those in **each of** the other grades.

339 (C) Medical female students (MS) exhibit a significantly higher HPV vaccination completion rate
340 (73.8%) compared to **each of** Health Science students (HS) and Pharmaceutic students (PS).

341 * $p<0.001$, NS, not significantly different. **Chi-square test and/or Fisher's exact test were**
342 **performed to compare between (B) the 6th year and the other academic years, as well as (C)**
343 **medical students and the other students.**

344

345 **Figure 3. Awareness of policy change for HPV vaccine recommendation in Japan**

346 (A) A significantly greater percentage of female medical students (89.3%) exhibited awareness of
347 both the suspension and the subsequent reinstatement of the vaccination policy in comparison to
348 their male counterparts (55.2%).

349 (B) Minimal disparities were detected across academic levels among female students.

350 (C) An elevation in awareness was observed concomitantly with the advancement of academic
351 year among male students.

352 * $p<0.001$, ** $p<0.05$, NS, not significantly different. **Chi-square test and/or Fisher's exact test**
353 **were performed to compare between the 6th year and the other academic years.**

354

355 **Figure 4. Healthcare students' self-assessment of knowledge regarding cervical cancer by**
356 **(A) sex, (B) academic level, and (C) affiliated department**

357 (A) The proportion of female students reporting that they were well-informed about cervical
358 cancer was significantly higher than that of male students (74.6% vs. 64.1%).

359 (B) The proportion of sixth-year students asserting well-informed status regarding cervical cancer
360 was significantly higher compared to students in the first to fourth years (94.9% vs. 57.4%, 54.6%,
361 76.8%, and 81.8%, sequentially by academic level).

362 (C) Medical students (MS) reported a significantly higher proportion of well-informed status
363 regarding cervical cancer compared to Health Science (HS) and Pharmaceutical students (PS)
364 (81.9% vs. 73.0% and 64.7%, respectively).

365 * $p<0.001$, ** $p<0.05$, NS, not significantly different. Chi-square test and/or Fisher's exact test
366 were performed to compare between (B) the 6th year and the other academic years, as well as (C)
367 medical students and the other students.

368

369 **Figure 5. The primary reasons for the HPV vaccination**

370